Mounjaro pens and the 5-dose question: what the licensed design actually means

What the licensed SmPC and clinical programme actually show

The Mounjaro SmPC on the electronic Medicines Compendium is unambiguous: one 0.5 ml subcutaneous injection once weekly, four injections per pen. Eli Lilly's manufacturing specification accounts for real-world delivery, the device overfills slightly so that the last plunger stroke delivers a full, accurate dose rather than a short one. That residual resistance at the end of pen four is the design working correctly.

The SURMOUNT-1 trial, which enrolled 2,539 adults and ran for 72 weeks, studied tirzepatide at consistent, protocol-specified doses and reported average body-weight reductions of around 20–21% at the 15 mg dose. Those results emerged from a programme where dosing discipline was tightly maintained. Dose consistency isn't incidental to the outcomes, it is baked into how the clinical evidence was generated, as NICE noted in its appraisal of tirzepatide (NICE TA1026).

Understanding the pen's structure is practical, not pedantic. Mounjaro is a prescription-only medicine; the schedule the prescriber sets is based on the four-dose pen cycle. Altering that (even by trying to stretch one pen) shifts the timing of your next clinical review and your next supply, in ways a prescriber needs to know about.

The residual liquid: what it is and what it isn't

A common assumption is that any medicine left in a pen must mean a dose was wasted. With Mounjaro, that's the wrong frame. Pharmaceutical manufacturers build overfill into single-use and multi-dose devices to compensate for the small volume that stays in the needle hub, the cartridge dead space, and the mechanical tolerance of the plunger. For a 0.5 ml weekly injection, even a fraction of a millilitre matters for accuracy.

What you can feel after the fourth injection is not a fifth dose sitting ready. It is the overfill volume, present specifically so that doses one through four arrive at the correct concentration. Extracting it with a different needle or technique would not give you 2.5 mg, 5 mg, or whichever strength you are prescribed; it would give you an unknown, sub-therapeutic fraction of that.

If you want to understand more about what each Mounjaro strength looks like in terms of volume, that detail is set out in the SmPC alongside injection technique guidance. The right source for your personal dosing schedule is always the Patient Information Leaflet that comes with your pen and your prescriber.

How this affects your pen supply and timing

Mounjaro is titrated in four-week steps, starting at 2.5 mg, then moving up as clinically appropriate, with the prescriber reviewing before each change. Because one pen equals four weeks of treatment, the pen cycle maps directly onto the clinical review cycle. That alignment is intentional.

If a patient tries to make a pen last five weeks, the mismatch cascades: the fifth injection is pharmacologically compromised, the sixth week starts without medicine in the system, and the prescriber's review timeline slips. For a medicine where dose adequacy at each stage affects both tolerability and outcomes, that matters.

Replacement timing, what to do if a dose is missed, and how to handle a pen that appears empty before four injections are all covered in the Patient Information Leaflet. Specific questions about your schedule (including whether switching strengths affects your pen count) are for your prescriber, not for a general guide. On the broader question of how Mounjaro pen doses are structured across the full range, there is more detail on that topic if it's useful background.

Pricing across the treatment programme is a separate but related question for many patients; a factual overview of how Mounjaro's UK list price has changed is worth reading if you're planning supply ahead of a dose increase.

Getting clinically reviewed before your next pen

Every Mounjaro repeat at nume is reviewed by a GPhC-registered Independent Prescriber before dispatch, not automatically issued. That review exists partly to confirm dosing is still appropriate and that the treatment is working as it should. It also means supply is tied to clinical oversight, which is how a prescription-only medicine is supposed to work.

If you have a specific question about your pen (how it feels, whether the injection completed properly, or what to do if you suspect a dose wasn't delivered correctly) that is exactly the kind of thing to raise through our aftercare team, who are available seven days a week. For general background on how Mounjaro works as a treatment, that page covers the mechanism and the licensed use in full. When you're ready to take the next step, you can check your eligibility through a free consultation with our prescribers.